KNOWLEDGESHIFT, LLC

Early R&D

Early R&D Biopharmaceutical sequencing plays a critical role in our research and development activities, providing the molecular insights needed to advance innovative therapeutic programs. Through advanced genomic, transcriptomic, and epigenetic sequencing technologies, we generate high-quality data that supports target identification, biomarker discovery, disease characterization, and candidate optimization.

Our sequencing capabilities are integrated throughout the development process, enabling researchers to better understand complex biological mechanisms and make data-driven decisions at every stage of discovery. These capabilities strengthen our ability to accelerate scientific progress, improve development efficiency, and support the creation of safe, effective, and targeted therapies that address unmet medical needs across a range of disease areas.

Industry Leading Sequencing

Knowledgeshift offers industry-leading laboratory techniques across the whole spectrum of R&D. From initial target identification and biomarker discovery to viral vector engineering and cell line, all the way through to gene, cell and RNA therapy drug development.

Our sequencing uncovers what you have been missing with other conventional assays and legacy sequencing technologies. With high-accuracy, any-length reads, we can achieve comprehensive variant analysis, capturing single nucleotide polymorphisms (SNPs) and large, complex structural variants (SVs), to determine any off-target effects and reduce risk. .

With simple and rapid workflows, we can easily perform:

Whole-genome sequencing

Bulk transcriptomics

Multiomics

Single-cell and spatial transcriptomics

Tumour-normal sequencing

Direct RNA sequencing

Plasmid sequencing

Adeno-associated virus sequencing

Nanopore-only microbial isolate sequencing

Amplicon sequencing

Find out more about solutions for cell and gene therapy

Next-generation sequencing is now an essential tool across the drug development value chain. However, the requirement of legacy sequencing technologies for nucleic acid fragmentation and amplification erases critical sample information. Knowledgeshift sequencing is able to overcome these limitations to reveal the true biology of samples.